Ocugen, Inc.

OCGN

Healthcare|Biotechnology|US

$0.93

+0.11 (+13.29%)

Cash / Share

$0.25

Next Earnings Report

Mar 3, 2027

EPS est. -$0.07 · Revenue est. $1.3M

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Jan 21, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Feb 2027

Est. completion

P3Retinitis Pigmentosa

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

NCT06388200n=140

Mar 2027

Est. completion

P1P2Retinitis Pigmentosa

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939n=22

Jul 2028

Est. completion

P3Dry Age-related Macular Degeneration

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

NCT07770828n=237

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026

P2P3

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

NCT05956626

Feb 2026

P1P2

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCT06018558

Recent Press Releases

Ocugen Provides Business Update with Third Quarter 2026 Financial Results

Nov 4, 2026 · GlobeNewsWire

Ocugen to Participate in Upcoming November Investor and Industry Conferences

Oct 29, 2026 · GlobeNewsWire

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Oct 22, 2026 · GlobeNewsWire

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Oct 14, 2026 · GlobeNewsWire

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Oct 8, 2026 · PRNewsWire

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Oct 7, 2026 · Newsfile Corp

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Oct 6, 2026 · GlobeNewsWire

Ocugen to Participate in Upcoming Scientific Conferences

Sep 30, 2026 · GlobeNewsWire

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Sep 29, 2026 · GlobeNewsWire

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Sep 25, 2026 · GlobeNewsWire

SEC Filings (90)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 6, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Nov 6, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Nov 4, 2026	10-Q	Quarterly report	Document Index
Nov 4, 2026	8-K	Material event	Document Index
Oct 15, 2026	8-K	Material event	Document Index
Oct 15, 2026	8-K	Material event	Document Index
Oct 6, 2026	8-K	Material event	Document Index
Sep 23, 2026	8-K	Material event	Document Index
Sep 8, 2026	8-K	Material event	Document Index
Aug 14, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Aug 13, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 7, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 6, 2026	10-Q	Quarterly report	Document Index
Aug 6, 2026	8-K	Material event	Document Index
Jul 30, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Jul 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Jul 29, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 20, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Jul 13, 2026	8-K	Material event	Document Index
Jun 11, 2026	8-K	Material event	Document Index
Jun 3, 2026	8-K	Material event	Document Index
May 14, 2026	8-K	Material event	Document Index
May 14, 2026	8-K	Material event	Document Index
May 8, 2026	10-Q	Quarterly report	Document Index
May 7, 2026	8-K	Material event	Document Index
May 5, 2026	8-K	Material event	Document Index
May 4, 2026	8-K	Material event	Document Index
Apr 28, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 28, 2026	ARS	Annual report to holders	Document Index
Apr 28, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 20, 2026	PRER14A		Document Index
Apr 17, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Apr 14, 2026	SC 13G	Passive 5%+ stake	Document Index
Mar 27, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Mar 27, 2026	8-K	Material event	Document Index
Mar 24, 2026	8-K	Material event	Document Index
Mar 20, 2026	8-K	Material event	Document Index
Mar 4, 2026	S-8	Employee stock plan	Document Index
Mar 4, 2026	10-K	Annual report	Document Index
Mar 4, 2026	8-K	Material event	Document Index